Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21472087 | 0.98 | HRH3 (0.65) | HRH3ALDH1A1MEN1CYP1A2CYP2D6 | |
| SCHEMBL10103384 | 0.98 | HRH3 (0.56) | HRH3ALDH1A1MEN1CYP1A2CYP2D6 | |
| SCHEMBL13849154 | 0.95 | HRH3 (0.61) | HRH3ALDH1A1MEN1CYP1A2CYP2D6 | |
| SCHEMBL96486 | 0.93 | HRH3 (0.56) | HRH3ALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL2331849 | 0.93 | HRH3 (0.56) | HRH3ALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL1277016 | 0.91 | HRH3 (0.52) | HRH3ALDH1A1MEN1CYP1A2CYP2D6 | |
| SCHEMBL21477136 | 0.90 | HRH3 (0.48) | HRH3ALDH1A1MEN1CYP1A2CYP2D6 | |
| SCHEMBL11574905 | 0.88 | — | — | |
| SCHEMBL25009132 | 0.88 | HRH3 (0.58) | HRH3ALDH1A1MEN1CYP1A2CYP2D6 | |
| SCHEMBL20325116 | 0.88 | HRH3 (0.52) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2019-02-07 | — | — | US | disclosed |
| CN-108570686-A | System and method for adjusting the gas concentration lwevel in internal ambience | 帕洛阿尔托研究中心公司 | 2018-09-25 | — | — | CN | disclosed |
| US-20170290819-A1 | SMALL MOLECULE THERAPIES FOR PULMONARY HYPERTENSION | CREIGHTON UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| EP-2041119-B1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2017-05-10 | — | — | EP | disclosed |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9233070-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9056045-B2 | Intraocular biodegradable microspheres | ALLERGAN, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20120258163-A1 | Tyrosine Kinase Microspheres | ALLERGAN, INC. | 2012-10-11 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-7771742-B2 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | ALLERGAN, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080260803-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer | ALLERGAN,INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | ALLERGAN,INC (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121665-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7335659-B2 | Substituted 10-aryl-11H-benzo[b]fluorenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors | N.V. ORGANON (NL) | 2008-02-26 | — | — | US | disclosed |
| US-7335659-B2 | Substituted 10-aryl-11H-benzo[b]fluorenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors | N.V. ORGANON (NL) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258163-A1 | Tyrosine Kinase Microspheres | KDR, FLT1, DSTYK | HRH3 2370/4885ALDH1A1 1896/4885MEN1 1316/4885 |
| US-20170290819-A1 | SMALL MOLECULE THERAPIES FOR PULMONARY HYPERTENSION | PTGIR, VASP, MYLK | HRH3 1009/4885ALDH1A1 1503/4885MEN1 3697/4885 |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | HRH3 3184/4885ALDH1A1 1951/4885MEN1 319/4885 |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | KDR, PTK2B, DSTYK | HRH3 2517/4885ALDH1A1 1500/4885MEN1 3077/4885 |
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | PTK2, CTTN, CRBN | HRH3 3687/4885ALDH1A1 3692/4885MEN1 2669/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | HRH3 2521/4885ALDH1A1 1537/4885MEN1 3082/4885 |
| US-20190038551-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | HRH3 2521/4885ALDH1A1 1537/4885MEN1 3082/4885 |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | VEGFA, PTK2, KDR | HRH3 3764/4885ALDH1A1 1521/4885MEN1 1851/4885 |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | FLT1, JAK1, KDR | HRH3 4038/4885ALDH1A1 4379/4885MEN1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.